血小板生成素依赖的髓系-巨核系造血促进血栓炎症并加重抗体介导的慢性肾脏微血管损伤
在小鼠抗体介导的慢性肾脏病(AMCKD)模型中,受损肾脏产生血小板生成素(TPO),刺激髓系-巨核系造血并加重微血管慢性血栓炎症;在伴血栓炎症和TGFβ依赖性肾小球硬化的新月体性肾小球肾炎患者中亦观察到TPO生物利用度升高;中和TPO可恢复正常造血、减轻血栓炎症并改善肾脏病变。
要点
- 小鼠AMCKD中受损肾脏产生TPO,驱动髓系-巨核系造血并加重微血管慢性血栓炎症。
- 新月体性肾小球肾炎患者伴血栓炎症、TGFβ依赖性肾小球硬化及TPO生物利用度升高。
- 小鼠中中和TPO可恢复正常造血、减少慢性血栓炎症并改善肾脏疾病。
核心结论
- TPO偏向性造血加重微血管慢性血栓炎症并恶化AMCKD,TPO既是相关生物标志物也是有前景的治疗靶点。
研究设计与样本
- 采用小鼠抗体介导的慢性肾脏病(AMCKD)模型并结合药理学干预,全面监测循环血、尿、骨髓和肾脏对损伤的应答。
- 分析新月体性肾小球肾炎患者血清白蛋白、造血生长因子和炎性细胞因子水平以识别治疗应答者。
主要发现
- 实验性AMCKD与慢性血栓炎症及受损肾脏产生造血生长因子(尤其TPO)相关,后者刺激并使造血向髓系-巨核系偏移。
- AMCKD以血管和肾脏功能障碍、TGFβ依赖性肾小球硬化和微血管稀疏为特征。
- 人类新月体性肾小球肾炎与血栓炎症、TGFβ依赖性肾小球硬化和TPO生物利用度升高相关。
- 小鼠中中和TPO使造血正常化、减少慢性血栓炎症并改善肾脏疾病。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Kidney-derived thrombopoietin (TPO) increases myeloid cell and platelet production during antibody-mediated chronic kidney disease (AMCKD) in a mouse model, exacerbating chronic thromobinflammation in microvessels. The effect is mirrored in patients with extracapillary glomerulonephritis associated with thromboinflammation, TGF β -dependent glomerulosclerosis, and increased bioavailability of TPO. Neutralization of TPO in mice normalized hematopoiesis, reduced chronic thromboinflammation, and ameliorated renal disease. The findings suggest that TPO is a relevant biomarker and a promising therapeutic target for patients with CKD and other chronic thromboinflammatory diseases.Neutralization of TPO in mice normalized hematopoiesis, reduced chronic thromboinflammation, and ameliorated renal disease. The findings suggest that TPO is a relevant biomarker and a promising therapeutic target for patients with CKD and other chronic thromboinflammatory diseases. BACKGROUND: Chronic thromboinflammation provokes microvascular alterations and rarefaction, promoting organ dysfunction in individuals with various life-threatening diseases. Hematopoietic growth factors (HGFs) released by the affected organ may sustain emergency hematopoiesis and fuel the thromboinflammatory process. METHODS: Using a murine model of antibody-mediated chronic kidney disease (AMCKD) and pharmacological interventions, we comprehensively monitored the response to injury in the circulating blood, urine, bone marrow, and kidney. RESULTS: Experimental AMCKD was associated with chronic thromboinflammation and the production of HGFs, especially thrombopoietin (TPO), by the injured kidney, which stimulated and skewed hematopoiesis toward myelo-megakaryopoiesis. AMCKD was characterized by vascular and kidney dysfunction, TGF β -dependent glomerulosclerosis, and microvascular rarefaction. In humans, extracapillary glomerulonephritis is associated with thromboinflammation, TGF β -dependent glomerulosclerosis, and increased bioavailability of TPO. Analysis of albumin, HGF, and inflammatory cytokine levels in sera from patients with extracapillary glomerulonephritis allowed us to identify treatment responders. Strikingly, TPO neutralization in the experimental AMCKD model normalized hematopoiesis, reduced chronic thromboinflammation, and ameliorated renal disease. CONCLUSION: TPO-skewed hematopoiesis exacerbates chronic thromboinflammation in microvessels and worsens AMCKD. TPO is both a relevant biomarker and a promising therapeutic target in humans with CKD and other chronic thromboinflammatory diseases.
引用
- Douté M, Sannier A, Even G, et al. Thrombopoietin-Dependent Myelo-Megakaryopoiesis Fuels Thromboinflammation and Worsens Antibody-Mediated Chronic Renal Microvascular Injury. J Am Soc Nephrol. 2023. PMID: 37022108. doi:10.1681/ASN.0000000000000127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。